The 2nd AACR-IASLC Joint Conference on the Molecular Origins of Lung Cancer: Pro

第二届 AACR-IASLC 肺癌分子起源联合会议：Pro

基本信息

批准号：
8257450
负责人：
Margaret Foti
金额：
$ 1万
依托单位：
AMERICAN ASSOCIATION FOR CANCER RESEARCH
依托单位国家：
美国
项目类别：
财政年份：
2011
资助国家：
美国
起止时间：
2011-09-16 至 2012-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8257450
关键词：
Academia Accounting Advocate American Association of Cancer Research American Cancer Society Area Attention Cancer Etiology Cessation of life Chemoprevention Clinical Collaborations Commit Complex Complication Diagnosis Discipline Disease Early Diagnosis Environmental Risk Factor Epidermal Growth Factor Receptor Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Epigenetic Process Erlotinib Gefitinib Gene Mutation Genes Genotype Individual Industry International Investigation Joints Lesion Lung Malignant Neoplasms Malignant neoplasm of lung Molecular Mutation Non-Small-Cell Lung Carcinoma Oncogenic Participant Patients Pharmaceutical Preparations Physicians Prevention Prevention therapy Reporting Research Research Personnel Resistance Schedule Scientist Screening procedure Selection for Treatments Series Students Technology Testing Therapeutic Clinical Trial Translational Research United States Woman anticancer research base cancer diagnosis cancer stem cell chemotherapeutic agent clinically relevant cytotoxic follow-up genetic variant insight lectures meetings men novel therapeutics planetary Atmosphere research and development response symposium tumor

项目摘要

DESCRIPTION (provided by applicant): The American Association for Cancer Research (AACR) and the International Association for the Study of Lung Cancer (IASLC) are jointly organizing a second conference on the Molecular Origins of Lung Cancer: Prospects for Personalized Prevention and Therapy to follow up on the successful 2010 conference. This second conference will take place January 8-11, 2012 at the San Diego Marriott Hotel & Marina in San Diego, CA and will focus on the molecular and translational aspects of lung cancer research. Lung cancer remains the most common cause of cancer death in the United States. The American Cancer Society estimates there were 222,520 new cases of lung cancer in 2010 (an increase since 2009) with 158,080 deaths1. The last 15 years of research have provided insight into the molecular nuances that stratify different types of non-small-cell lung cancer (NSCLC). In the past an approach to target all NSCLC with cytotoxic chemotherapeutic agents, a "one size fits all approach," provided a small measureable benefit but often with response rates of less than 20%2. Most recently, common molecular subtypes of NSCLC have been found, allowing for more targeted and subtype-based treatment selection. The most studied genetic variant in NSCLC is mutation in the gene encoding EGFR. Patients with this mutation have a better response rate to EGFR tyrosine kinase inhibitors, such as gefitinib or erlotinib, than those without the EGFR mutation. Similarly in 2010, the molecular subtype of NSCLC with ALK fusions emerged to the forefront as a clinically relevant and treatable oncogenic mutation. The ALK fusion subtype of NSCLC responds to a different drug than those lesions with an EGFR mutation (~57% response rate to crizotinib), highlighting the need to understand an individual's tumor genotype for optimal treatment. Emerging advances in the field of lung cancer research that require multi-disciplinary attention are: genetic mutations that confer resistance to treatment, the other molecular sub-types of lung cancer, and the possibility of screening for early detection reported in the results of the November 2010 NCI National Lung Screening Trial. This conference will bring together over 300 investigators from the basic, clinical, and translational disciplines of lung cancer research and provide them with a venue to discuss their recent advances, test new hypotheses, and establish new collaborations. As in our past successful conference, presenters will also discuss molecular mechanisms of chemoprevention, early detection, cancer stem cells, epigenetics, novel therapeutics, clinical trial results, and many other topics. This conference is not only a dynamic collaboration of the AACR and the IASLC, two organizations committed to the study of cancer, but also a dynamic collaboration of the many types of scientists and advocates that are needed for the well-rounded study and treatment of this disease. PUBLIC HEALTH RELEVANCE: Lung cancer remains the most common cause of cancer death in the United States and accounts for 29% and 26% of cancer-related deaths in men and women, respectively. The American Cancer Society estimates there were 222,520 new cases of lung cancer in 2010, accounting for ~14-15% of all new cases of cancer diagnosed (an increase since 2009)1. Given the complex underlying genetic alterations in tumors and the complication of contributing environmental factors, it is critical to gain a better understanding of the disease from the view of patient advocates, physicians, basic, translational, and clinical scientists. This forum, provided by the collaboration of AACR and IASLC, will be critical for developing new ways of diagnosing, studying, and treating lung cancer.

描述（由申请人提供）：美国癌症研究协会（AACR）和国际肺癌研究协会（IASLC）共同组织了第二次关于肺癌分子起源的会议：个性化预防和治疗的前景，以跟进2010年成功的2010年会议。第二次会议将于2012年1月8日至11日在加利福尼亚州圣地亚哥的圣地亚哥万豪酒店和码头举行，并将重点关注肺癌研究的分子和转化方面。在美国，肺癌仍然是癌症死亡的最常见原因。美国癌症协会估计，2010年有222,520例新的肺癌病例（自2009年以来增加），死亡人数为158,080例。最后15年的研究提供了对分析不同类型的非小细胞肺癌（NSCLC）的分子细微差别的见解。在过去，一种用细胞毒性化学治疗剂靶向所有NSCLC的方法，“一个尺寸适合所有方法”，提供了一个较小的可测量益处，但通常响应速率小于20％2。最近，已经发现了NSCLC的常见分子亚型，从而可以进行更多靶向和亚型的治疗选择。 NSCLC中研究最多的遗传变异是编码EGFR的基因中的突变。该突变患者对EGFR酪氨酸激酶抑制剂（例如Gefitinib或Erlotinib）的反应率要比没有EGFR突变的患者更好。同样，在2010年，NSCLC的分子亚型带有ALK融合量作为临床相关且可治疗的致癌突变。 NSCLC的ALK融合亚型对与EGFR突变的病变的反应不同（对Crizotinib的缓解率约为57％），强调需要了解个人的肿瘤基因型以进行最佳治疗。需要多学科关注的肺癌研究领域的新兴进步是：赋予治疗耐药性的基因突变，肺癌的其他分子亚类型，以及2010年11月NCI国家肺肺筛查试验结果中筛查早期检测的可能性。这次会议将汇集来自肺癌研究基本，临床和转化学科的300多名调查员，并为他们提供讨论他们最近的进步，检验新的假设并建立新合作的场所。与过去的成功会议一样，演示者还将讨论化学预防，早期检测，癌症干细胞，表观遗传学，新型治疗学，临床试验结果以及许多其他主题的分子机制。这次会议不仅是AACR和IASLC的动态合作，这是两个致力于癌症研究的组织，而且是多种类型的科学家和拥护者的动态合作，这些组织是对这种疾病进行全面研究和治疗所需的。公共卫生相关性：在美国，肺癌仍然是癌症死亡的最常见原因，分别占男性和女性癌症相关死亡的29％和26％。美国癌症协会估计，2010年有222,520例新的肺癌病例，占所有被诊断为癌症的新病例的14-15％（自2009年以来增加）1。鉴于肿瘤的基本遗传改变以及促成环境因素的并发症的复杂性，从患者拥护者，医生，基本，翻译和临床科学家的观点中更好地了解该疾病至关重要。该论坛由AACR和IASLC的合作提供，对于开发新的诊断，研究和治疗肺癌的方法至关重要。